Treatment of vocal fold scarring with autologous bone marrow-derived human mesenchymal stromal cells—first phase I/II human clinical study: commentary to response

We would like to thank for the interest for the article and comments in the response. We believe that cell therapy may offer a treatment for severe voice problems in patients with vocal fold scarring and MSC treatment is a valuable alternative.

Detalles Bibliográficos
Autores principales: Hertegård, Stellan, LeBlanc, Katarina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7298817/
https://www.ncbi.nlm.nih.gov/pubmed/32546218
http://dx.doi.org/10.1186/s13287-020-01748-x
_version_ 1783547277817675776
author Hertegård, Stellan
LeBlanc, Katarina
author_facet Hertegård, Stellan
LeBlanc, Katarina
author_sort Hertegård, Stellan
collection PubMed
description We would like to thank for the interest for the article and comments in the response. We believe that cell therapy may offer a treatment for severe voice problems in patients with vocal fold scarring and MSC treatment is a valuable alternative.
format Online
Article
Text
id pubmed-7298817
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72988172020-06-17 Treatment of vocal fold scarring with autologous bone marrow-derived human mesenchymal stromal cells—first phase I/II human clinical study: commentary to response Hertegård, Stellan LeBlanc, Katarina Stem Cell Res Ther Commentary We would like to thank for the interest for the article and comments in the response. We believe that cell therapy may offer a treatment for severe voice problems in patients with vocal fold scarring and MSC treatment is a valuable alternative. BioMed Central 2020-06-16 /pmc/articles/PMC7298817/ /pubmed/32546218 http://dx.doi.org/10.1186/s13287-020-01748-x Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Commentary
Hertegård, Stellan
LeBlanc, Katarina
Treatment of vocal fold scarring with autologous bone marrow-derived human mesenchymal stromal cells—first phase I/II human clinical study: commentary to response
title Treatment of vocal fold scarring with autologous bone marrow-derived human mesenchymal stromal cells—first phase I/II human clinical study: commentary to response
title_full Treatment of vocal fold scarring with autologous bone marrow-derived human mesenchymal stromal cells—first phase I/II human clinical study: commentary to response
title_fullStr Treatment of vocal fold scarring with autologous bone marrow-derived human mesenchymal stromal cells—first phase I/II human clinical study: commentary to response
title_full_unstemmed Treatment of vocal fold scarring with autologous bone marrow-derived human mesenchymal stromal cells—first phase I/II human clinical study: commentary to response
title_short Treatment of vocal fold scarring with autologous bone marrow-derived human mesenchymal stromal cells—first phase I/II human clinical study: commentary to response
title_sort treatment of vocal fold scarring with autologous bone marrow-derived human mesenchymal stromal cells—first phase i/ii human clinical study: commentary to response
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7298817/
https://www.ncbi.nlm.nih.gov/pubmed/32546218
http://dx.doi.org/10.1186/s13287-020-01748-x
work_keys_str_mv AT hertegardstellan treatmentofvocalfoldscarringwithautologousbonemarrowderivedhumanmesenchymalstromalcellsfirstphaseiiihumanclinicalstudycommentarytoresponse
AT leblanckatarina treatmentofvocalfoldscarringwithautologousbonemarrowderivedhumanmesenchymalstromalcellsfirstphaseiiihumanclinicalstudycommentarytoresponse

Ejemplares similares